Skip to content
MDGLMadrigal Pharmaceuticals, Inc.

Earnings

When Madrigal Pharmaceuticals, Inc. reports, what it reported each quarter, and how the stock took the results.

66 quarters. Jun 30, 2010 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Feb 18, before the open

Thu, Feb 18, 2027in 92 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 22 – Mar 2

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$321.08M
Revenue, change from a year earlier: Q3 2026 +50.1%, Q2 2026 +71.2%, Q1 2026 +126.8%, Q4 2025 +210.8%
Net income
-$58.58M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$431.27M+50.1% vs Q3 2025

Latest results

  1. Q3 2026Nov 3, 2026, before the openThe release8.1%by the close of Nov 3
    Revenue
    $431.27M
    +50.1%
    Net income
    $55.44M
    N/M
    EPS
    $1.83
    N/M
    Third-quarter 2026 net revenues were $431.3 million, an increase of 50% compared to $287.3 million in the comparable prior year period, driven by increased demand for Rezdiffra in the U.S. in 2026.
  2. Q2 2026Jul 30, 2026, before the openThe release9.9%by the close of Jul 30
    Revenue
    $364.25M
    +71.2%
    Net income
    -$57.94M
    N/M
    EPS
    -$1.99
    N/M
  3. Q1 2026May 6, 2026, before the openThe release+7.5%by the close of May 6
    Revenue
    $311.34M
    +126.8%
    Net income
    -$94.39M
    N/M
    EPS
    -$3.25
    N/M
  4. Q4 2025Feb 19, 2026, before the openThe release11.1%by the close of Feb 19
    Revenue
    $321.08M
    +210.8%
    Net income
    -$58.58M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 3, 2026 · pre-marketNov 3, 202634 d10-Q$431.27M+50.1%$1.838.1%
Q2 2026Jun 30, 2026Jul 30, 2026 · pre-marketJul 30, 202630 d10-Q$364.25M+71.2%-$1.999.9%
Q1 2026Mar 31, 2026May 6, 2026 · pre-marketMay 6, 202636 d10-Q$311.34M+126.8%-$3.25+7.5%
FY 2025
Q4 2025derivedDec 31, 2025Feb 19, 2026 · pre-marketFeb 19, 202650 d10-K$321.08M+210.8%—11.1%
Q3 2025Sep 30, 2025Nov 4, 2025 · pre-marketNov 4, 202535 d10-Q$287.27M+362.0%-$4.01+7.7%
Q2 2025Jun 30, 2025Aug 5, 2025 · pre-marketAug 5, 202536 d10-Q$212.80M+1,353.8%-$1.50+8.4%
Q1 2025Mar 31, 2025May 1, 2025 · pre-marketMay 1, 202531 d10-Q$137.25M—-$2.612.0%
FY 2024
Q4 2024derivedDec 31, 2024Feb 26, 2025 · pre-marketFeb 26, 202557 d10-K$103.32M——+14.8%
Q3 2024Sep 30, 2024Oct 31, 2024 · pre-marketOct 31, 202431 d10-Q$62.18M—-$4.92+20.1%
Q2 2024Jun 30, 2024Aug 7, 2024 · pre-marketAug 7, 202438 d10-Q$14.64M—-$7.1012.2%
Q1 2024Mar 31, 2024May 7, 2024 · pre-marketMay 7, 202437 d10-Q$0.00—-$7.3812.2%
Earlier years, FY 2010 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 3, 2026069145
10-QJul 30, 2026050845
10-QMay 6, 2026030947
10-KFeb 19, 2026009514
10-QNov 4, 2025048559
10-QAug 5, 2025037613
10-QMay 1, 2025021356
10-KFeb 26, 2025007980
10-QOct 31, 2024044445
10-QAug 7, 2024035400

Provenance

ProvenanceData status and checks

Madrigal Pharmaceuticals, Inc. · CIK 1157601 · Engraved from SEC EDGAR